Summary
Boston Scientific Corporation (BSX) announced the completion of its acquisition of Millipede, Inc. on January 29, 2019. This strategic move, following earlier option agreements and approvals under the Hart-Scott Rodino Act, significantly expands BSX's cardiovascular portfolio. Millipede's flagship product, the IRIS Transcatheter Annuloplasty Ring System, is designed to treat severe mitral regurgitation, a condition that affects a substantial patient population and represents a growing market opportunity. The acquisition positions Boston Scientific to capitalize on advancements in transcatheter therapies. The IRIS system offers a less invasive treatment option compared to traditional surgical methods, aligning with the industry's trend towards percutaneous interventions. Investors should view this acquisition as a positive step towards strengthening BSX's competitive position in the high-growth structural heart market and driving future revenue streams through innovative medical devices.
Key Highlights
- 1Boston Scientific (BSX) has officially acquired Millipede, Inc., as of January 29, 2019.
- 2The acquisition is a significant expansion into the treatment of severe mitral regurgitation.
- 3Millipede's key asset is the IRIS Transcatheter Annuloplasty Ring System.
- 4The IRIS system represents a less invasive, transcatheter approach to treating mitral regurgitation.
- 5Acquisition completed after the expiration of the Hart-Scott Rodino Act waiting period.
- 6This move strengthens BSX's position in the cardiovascular and structural heart device market.